Therapeutische Probleme bei der Behandlung des v.-Willebrand-Syndroms
暂无分享，去创建一个
[1] P. Mannucci,et al. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. , 1992, Blood.
[2] J. Ware,et al. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[3] D. Ginsburg,et al. Molecular basis of human von Willebrand disease: analysis of platelet von Willebrand factor mRNA. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[4] E. Berntorp,et al. Use of a High‐Purity Factor VIII Concentrate (Hemate P) in von Willebrand's Disease 1 , 1989, Vox sanguinis.
[5] J. Gadarowski,et al. Humate-P for treatment of von Willebrand disease. , 1988, Blood.
[6] P. Mannucci,et al. Absence of hepatitis after treatment with a pasteurized factor VIII concentrate in patients with hemophilia and no previous transfusions. , 1987, The New England journal of medicine.
[7] H. Roberts,et al. Antihemophilic factor concentrate therapy in von Willebrand disease. Dissociation of bleeding-time factor and ristocetin-cofactor activities. , 1976, JAMA.
[8] I. Scharrer. Einführung: Zur Therapie des von Willebrand-Syndroms , 1987 .